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Summary In the United States (U.S.), federal legislation requiring the use of
safety-engineered sharp devices, along with an array of other protective measures,
has played a critical role in reducing healthcare workers’ (HCWs) risk of occupa-
tional exposure to bloodborne pathogens over the last 20 years. We present the
history of U.S. regulatory and legislative actions regarding occupational blood expo-
sures, and review evidence of the impact of these actions. In one large network
of U.S. hospitals using the Exposure Prevention Information Network (EPINet) sharps
injury surveillance program, overall injury rates for hollow-bore needles declined by
34%, with a 51% decline for nurses. The U.S. experience demonstrates the effective-
ness of safety-engineered devices in reducing sharps injuries, and the importance of
national-level regulations (accompanied by active enforcement) in ensuring wide-
scale availability and implementation of protective devices to decrease healthcare
worker risk.
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The protection of healthcare workers (HCWs)
rom exposures to bloodborne pathogens, a
ife-threatening occupational risk in healthcare set-
ings, was tragically neglected in the pre-AIDS era.
uch exposures, particularly to hepatitis B, long
xacted a deadly toll among HCWsworldwide. But it
as not until the global AIDS epidemic captured the
ttention of the healthcare community that efforts
o reduce this grave occupational risk were set in
otion. United States (U.S.) federal agencies intro-
uced and then mandated a comprehensive array
f countermeasures, and succeeded in achieving
igniﬁcant reductions in occupational risk to the
ational healthcare workforce. The actions taken
n the U.S. over the past 20 years can thus provide
useful model, with caveats, for other countries
hat are presently at earlier stages of progress.
The ﬁrst case of needlestick-transmitted HIV
as reported in the Lancet in 1984, alerting the
ealthcare community to this new threat [1]. In
987, the Centers for Disease Control and Preven-
ion (CDC) documented six cases of occupationally
cquired HIV infection in the U.S. [2], a report that
ent shock waves through the healthcare commu-
ity. Pressure was applied to government agencies
o take protective action, and a large healthcare
orker union formally petitioned the Occupational
afety and Health Administration (OSHA), an agency
f the U.S. Department of Labor with authority
ver employers, to set a new standard requiring
ealthcare employers to upgrade protective mea-
ures provided to employees. This began a process
hat lasted more than a decade, during which many
olicy actions were initiated in the complicated
egulatory and legislative environment of the U.S.
The CDC was the ﬁrst federal agency to respond.
n 1987, it issued guidelines for Universal Precau-
ions for workers at risk of exposure to the blood or
ody ﬂuids of patients [3]. The guidelines applied
o all bloodborne pathogens, and recommended:
1) increased use of personal protective equipment
PPE) such as gloves, ﬂuid-resistant gowns, protec-
ive eyewear, masks and other barrier garments to
educe contact with blood and contaminated body
uids; (2) safer handling and disposal of sharp med-
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cal devices; (3) hepatitis B vaccine offered at no
ost to employees; (4) use of puncture-resistant
harps containers, placed as close as possible to the
oint-of-use; and (5) annual training of all at-risk
orkers in the protective measures included in the
uidelines [3].
OSHA issued an advisory notice to employers in
987 which incorporated the CDC guidelines [4]; in
hat same year, it initiated procedures for estab-
ishing a regulatory standard covering employee
xposures to bloodborne pathogens [5]. After sev-
ral years of hearings and public comment, and
ntense congressional pressure, the standard was
romulgated in 1991 [6]. To this day, the OSHA
loodborne Pathogens Standard (BPS) remains the
rincipal authority protecting U.S. HCWs from
loodborne pathogens.
athogen-speciﬁc prevention and
nterventions
he 1987 recommendations from the CDC and OSHA
ere followed by a rapid increase in hepatitis B vac-
ination rates. The incidence of occupational HBV
nfections declined dramatically, from more than
7,000 cases in 1983, before the availability of the
accine, to 400 in 1995 — a 95% decline [7].
OSHA’s 1987 advisory notice and the 1991 BPS
oth included provisions requiring employers to
ecord and track occupational blood exposures, and
o offer exposed employees follow-up counseling
nd treatment, including post-exposure chemopro-
hylaxis (PEP), when medically appropriate [4,6].
he use of anti-retroviral (ARV) drugs for HIV
EP was a signiﬁcant advance in preventing occu-
ational transmission of HIV. In 1997, the CDC,
eporting on the results of a case-control study,
aid ‘‘the odds of HIV infection among health care
orkers who took zidovudine prophylactically after
xposure were reduced by approximately 81 per-
ent’’ [8]. The following year, the CDC issued
linical guidelines on the use of combination ARV
herapy (believed to be more effective than treat-
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ment with zidovudine alone) for PEP to reduce
HCWs’ risk of infection after an exposure to HIV
[9].
The rapid adoption of ARV drugs by HIV/AIDS
patients also had a profound effect on HCWs’ HIV
exposure and infection risk: hospital admissions of
HIV/AIDS patients declined dramatically [10,11],
and those on ARV therapy who were hospitalized
posed less infection risk to HCWs, since they usu-
ally have low (in some cases undetectable) viral
loads. The combination of these factors resulted
in a marked decrease in HIV transmission risk
to hospital-based HCWs. Through 1997, 54 docu-
mented and 132 possible cases of occupational HIV
infection were reported in the U.S.; after 1997,
only three additional documented and ﬁve possible
cases were reported. Since 2001, there has been
only one possible case of occupationally transmit-
ted HIV/AIDS reported in the U.S. [10—12].
Prevention of sharps injuries
The safety-related work practices outlined in the
CDC’s Universal Precautions and OSHA’s joint advi-
sory in 1987 were the ﬁrst steps towards reducing
sharps injury risk to U.S. HCWs [3,4]. These
work practices included a prohibition (with a few
exceptions) on the recapping of contaminated nee-
dles, and provision of puncture- and ﬂuid-resistant
sharps disposal containers at the point-of-use,
preferably within arms’ reach of the user. Place-
ment of sharps containers in patient rooms and
other point-of-use locations reduced the incentive
of HCWs to recap used needles: one study reported
that the implementation of point-of-use sharps con-
tainers lowered recapping-associated needlesticks
from 23% of all needlesticks in 1986 to only 5% in
1992—1994 [13].
The greatest impact on sharps injury risk,
however, resulted from the adoption of safety-
engineered needles and sharp devices designed
to reduce the incidence of sharps injuries to
users. From their ﬁrst appearance on the market
around 1988 to the passage of a national needle-
stick law in the U.S. in 2000, a progression of
policies were implemented by government agen-
cies, state legislatures and the U.S. Congress that
ﬁrst recommended, then required, their use. As
early as 1987, OSHA speciﬁed that ‘‘engineering
controls’’ were the preferred method of hazard
reduction to prevent HCWs’ exposure to blood
[4]. Safety-engineered needles and sharp devices
are considered engineering controls; however, they
were not available in 1987, and therefore were not
•J. Jagger et al.
peciﬁed in the joint advisory. But by 1990, the
ajor medical device manufacturers had embraced
he concept of safety-engineered needles and
harps, resulting in the rapid development of new
harps safety technology. By 1996, there were more
han 1000 U.S. patents issued for medical devices
ith sharps safety features [14]. The new technol-
gy addressed the full spectrum of sharp devices,
ncluding injection devices, vascular access and
lood-drawing devices, surgical instruments and
aboratory equipment. The investment of U.S. med-
cal device manufacturers in the development of
his technology was critical to efforts to create a
afer healthcare workplace.
The national movement to require the use of
afety-engineered devices began around 1990, with
umerous advocacy groups pulling all possible legal
nd regulatory levers to see which ones would have
he desired effect. Healthcare worker unions, nurs-
ng and infection control professional associations,
edical device manufacturers, state government
fﬁcials, and academic researchers all embraced
he common goal.
The ﬁrst government policy with noticeable
mpact on the use of needle devices was a ‘‘Safety
lert’’ issued by the Food and Drug Administration
FDA) in 1992, following a request from the health-
are community [15]. The safety alert advised
ealthcare institutions to stop using hypodermic
eedles for accessing I.V. ports and connecting
.V. lines (piggyback needles), and to preferentially
dopt needleless I.V. connectors and I.V. access
yringes (usually used for heparin/saline ﬂushes).
lthough compliance with an FDA safety alert is
oluntary, they are taken seriously by hospitals.
ollowing publication of the 1992 alert, the medi-
al device industry reported a dramatic increase in
emand for needleless I.V. equipment. And a report
f trends in needlestick injuries among nurses
howed that between 1993 and 2001 there was a
00% drop in injuries from I.V. line connectors, pre-
iously one of the most common causes of injury,
nd a 62% drop in injuries from preﬁlled syringes
used for heparin/saline ﬂushes) [16].
The FDA alert was also signiﬁcant because it
rovided language that became the foundation for
eﬁning devices designed to reduce needlestick
njuries, including:
A ﬁxed safety feature to provide a barrier
between the hands and the needle after use; the
safety feature should allow or require the hands
to remain behind the needle at all times.
The safety feature [is] an integral part of the
device, and not an accessory.
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The safety feature [is] in effect before disas-
sembly and [remains] in effect after disposal, to
protect users and trash handlers, and for envi-
ronmental safety.
The safety feature [is] as simple as possible, and
[requires] little or no training to use effectively
[15].
In 1999, the FDA also issued a ‘‘Safety Advisory’’
n the hazards of glass microhematocrit capillary
ubes, which were prone to breakage and pre-
ented a serious risk of injury and blood exposure
o HCWs. The advisory, issued jointly with OSHA
nd the National Institute for Occupational Safety
nd Health (NIOSH), warned against the use of glass
apillary tubes and recommended instead plastic or
lastic-wrapped tubes [17]. The safety advisory had
signiﬁcant impact. In U.S. sharps injury data from
994 to 1998 (prior to the advisory being issued),
he total number of reported injuries from glass
apillary tubes was 33; for the period 2000—2004,
fter the advisory was issued, the total number
f injuries from glass capillary tubes dropped to
[18].
Pressure in the U.S. to legally require devices
ith sharps injury protection grew as more
afety devices were introduced to the health-
are market and evidence of their effectiveness
ecame available. Clinical trials and product
valuations were published on safety-engineered
lood-drawing devices, vascular access devices,
lunt suture needles, syringes, and needleless
.V. equipment, all of which demonstrated the
ffectiveness of the new technology in reducing
eedlestick injury risk. The degree of efﬁcacy var-
ed but was generally high, ranging from two-thirds
eduction in injuries for safety phlebotomy devices
o more than 80% reduction for safety I.V. catheters
19—28].
Healthcare worker unions became a driving force
n introducing legislation at the state level, part
f a larger strategy to ultimately achieve a sin-
le federal law. In 1998, California passed the ﬁrst
tate law requiring employers to provide safety-
ngineered sharp devices in all relevant device
ategories [29]. Medical device manufacturers had
o scale up production of safety devices to meet
arket demand for the most highly populated U.S.
tate [30]. Sixteen additional states passed simi-
ar laws in the next two years [31]; this patchwork
f state laws created havoc for manufacturers and
ospital procurement organizations, and provided
urther incentive to pass a uniform national law.
The federal government recognized the need
o assess potential costs and beneﬁts of mandat-
ng safety-engineered sharp devices at a national
r
e
t
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evel. To this end, OSHA issued a ‘‘Request for
nformation’’ (RFI) in 1998 soliciting comments
nd documentation on workplace experiences with
ngineering controls designed to minimize occu-
ational exposure to bloodborne pathogens from
ercutaneous injuries. A summary of responses
rom more than 400 healthcare facilities was pub-
ished in May 1999; OSHA concluded that ‘‘safer
edical devices are an effective and feasible
ethod of hazard control [32].’’
The federal government’s Ofﬁce of Manage-
ent and Budget was commissioned to perform
cost/beneﬁt assessment of the national impact
f adopting safety-engineered sharps. This report,
ssued in 2000, provided further support for
he beneﬁts of the technology and its cost-
ffectiveness if adopted nationwide [33].
As a result of the supporting evidence provided
y the RFI, OSHA revised the compliance directive
or the BPS, giving OSHA inspectors the authority
o issue citations and levy ﬁnes against healthcare
mployers who failed to provide safety-engineered
harps in their facilities [34]. The 1999 revised com-
liance directive stated that ‘‘Where engineering
ontrols will reduce employee exposure either by
emoving, eliminating or isolating the hazard, they
ust be used’’ [emphasis added]; it said further
hat ‘‘Signiﬁcant improvements in technology are
ost evident in the growingmarket of safer medical
evices that minimize, control or prevent exposure
ncidents [34].’’
he Needlestick Safety And Prevention
ct of 2000
he U.S. Congress determined that language in
he OSHA BPS relating to needlesticks and sharps
afety needed to be expanded for greater clarity.
he Needlestick Safety and Prevention Act (NSPA)
f 2000, which required OSHA to revise the BPS
or this purpose, was unanimously passed by both
ouses of Congress, and was signed into law by Pres-
dent Clinton on November 6, 2000 [35]. The law
equired that: (1) frontline HCWs (those providing
irect patient care) be included in the process of
valuating and selecting safety-engineered needles
nd sharps; (2) employers document evaluation and
mplementation of safety-engineered devices; (3)
mployers update their evaluation plan annually to
eﬂect the availability of new technology; and (4)
mployers maintain a sharps injury log documenting
he types of devices causing injuries and an expla-
ation of the circumstance of each incident. OSHA
ade these revisions to the BPS in compliance with
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the new law, and the revised standard took effect
in April 2001 [36].
Deﬁnition of ‘‘safety-engineered’’ sharp
devices; exemptions; training
The 2001 revised BPS deﬁned a ‘‘sharp with engi-
neered sharps injury protection’’ (SESIP) as a
‘‘non-needle sharp or needle device used for with-
drawing body ﬂuids, accessing a vein or artery, or
administering medications or other ﬂuids, with a
built-in safety feature or mechanism that effec-
tively reduces the risk of an exposure incident
[36].’’ This deﬁnition allowed for a variety of
injury-prevention design solutions and avoided
mandating speciﬁc features or brands. It also
encouraged the broad participation of industry in
designing a wide range of innovative products.
Under the revised standard, safety-engineered
devices are not required for applications which
do not involve direct patient contact (e.g., mix-
ing drugs in the pharmacy) [37]. Also, exemptions
from using safety devices are allowed in spe-
ciﬁc clinical circumstances. OSHA states that ‘‘No
one medical device is appropriate in all circum-
stances of use. For purposes of this standard, an
‘appropriate’ safer medical device includes only
devices whose use, based on reasonable judgment
in individual cases, will not jeopardize patient or
employee safety or be medically contraindicated’’
[36]. OSHA further explains: ‘‘If a safer device is
not available in the marketplace, the employer is
not required to develop any such device. Further-
more, the revised requirements are limited to the
safer medical devices that are considered to be
‘effective’ [. . .] a device that, based on reasonable
judgment, will make an exposure incident involv-
ing a contaminated sharp less likely to occur in the
application in which it is used’’ [36].
Although safety devices are usually more expen-
sive than conventional ones, OSHA does not allow
exemptions based solely on cost. In a letter to
the American Academy of Pediatrics, OSHA stated:
‘‘The standard does not give the employer the
option to forgo appropriate, commercially avail-
able, and effective engineering controls’’ [38].
Elsewhere OSHA says, ‘‘[S]electing a safer device
based solely on the lowest cost is not appropriate.
Selection must be based on employee feedback and
device effectiveness’’ [39].
Regarding training of employees on the use
of safety devices, OSHA emphasized that training
should include ‘‘an explanation of the use and lim-
itations of [. . .] appropriate engineering controls’’
c
c
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nd ‘‘instruction in any new techniques and prac-
ices’’ [36].
The chief importance of the federal law was to
ive high-proﬁle visibility to the requirement to use
afety-engineered devices, and to provide a sin-
le standard of protection for all U.S. HCWs. The
aw, combined with active enforcement by OSHA,
esulted in high levels of compliance by healthcare
nstitutions nationwide.
nforcement and compliance
etween 2001 and 2005, the number of citations
ssued by OSHA for failure to use engineering and
ork practice controls was four times that issued
or this class of violation in the previous decade.
etween 2001 and 2007, OSHA issued 144 cita-
ions and levied $389,800 in ﬁnes against healthcare
acilities for failure to comply with the requirement
o use safety devices (personal communication,
ionne Williams, Ofﬁce of Health Enforcement,
SHA, 2008). Such punitive enforcement actions
re taken very seriously by U.S. hospitals, since
SHA citations are made public and a hospital’s rep-
tation can be adversely affected by bad publicity.
A dramatic surge in adoption rates of safety-
ngineered devices occurred in 2000 and 2001.
he only national data available that reﬂect over-
ll compliance with the requirement to use safety
evices come from the medical device industry;
ndustry data (from sources reﬂecting all manu-
acturers and the total U.S. device market) show
ational market trends for adoption of safety
evices in three device categories (Fig. 1) [40].
rom 1990 to 2000, there was a gradual adoption of
afety devices, but the voluntary rate of adoption
as generally low — 25% or less for most device cat-
gories [41]. Adoption rates climbed sharply after
000, with safety-engineered devices becoming the
redominant technology over the following three
ears [40]. Encouragingly, adoption rates were par-
icularly high for the types of devices with the
ighest risk of bloodborne pathogen transmission:
lood collection needles and I.V. catheters.
mpact of the law on injury rates
ssessing the overall impact of the U.S. law is
omplicated by the fact that, in most cases, a clear-
ut before-and-after comparison of data cannot
e made, since the adoption of safety technology
ccurred gradually during the 1990s. However, one
ospital in the U.S., Memorial Sloan-Kettering Can-
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tigure 1 Increase in percent market share of three safe
.S. hospitals; data for 1998 and 2001 additionally includ
er Center (MSK) in New York City, documented an
xperience in which no safety devices were in use
efore the law was passed, followed by a near-total
onversion to safety-engineered devices after the
aw took effect [42]. The MSK study showed an over-
ll reduction in sharps injuries of 58%, with a 71%
eduction in injuries from hollow-bore needles, and
75% reduction among nurses, the occupational
roup that typically sustains the highest proportion
f injuries.
A group of U.S. hospitals using the Exposure Pre-
ention Information Network (EPINet) program for
urveillance of occupational blood exposures has
articipated in a data-sharing network with the Uni-
ersity of Virginia since 1993; these hospitals, like
ost in the U.S., gradually adopted various safety-
t
t
i
I
igure 2 Injury rates from hollow-bore needles: safety ver
otal injuries = 18,975 (excludes injuries occurring before useevices, U.S., 1998—2003. 1998—2005 data represents all
lternate sites (clinics, ofﬁces, labs).
ngineered devices between 1993 and 2000. For
his reason, EPINet network data from before and
fter the NSPA do not reﬂect as sharp a distinction
s in the MSK study. Fig. 2 shows annual injury rates
rom hollow-bore needles in the EPINet network
uring the period 1993—2004 (cumulative total of
7 U.S. hospitals contributing data); injury rates
ropped by 34% after passage of the NSPA in 2000.
onsistent with the MSK study, nurses as an occupa-
ional group showed the largest reduction in injury
ates (51%) [16].
Device-speciﬁc injury rates (Fig. 3) show thathe largest reductions in rates were seen for
he devices with the highest market penetration,
ncluding phlebotomy needles (59% reduction) and
.V. catheter stylets (53% reduction). These two
sus conventional, U.S. EPINet 1993—2004. 87 hospitals;
of device).
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Figure 3 U.S. EPINet: device-speciﬁc injury rates before (1993—2000) and after (2001—2004) passage of Needlestick
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aSafety and Prevention Act (November 2000). 87 hospital
use of device).
device categories are among those with the highest
risk of bloodborne pathogen transmission; convert-
ing to safety in these categories is likely to have
the greatest impact on reducing transmission risk
to HCWs. Fig. 3 also shows that there is resid-
ual use of conventional devices; injury rates would
decline further with 100% conversion to safety
in device categories where that goal is feasible.
(There remain legitimate non-patient applications
for conventional syringes, for example.)
Fig. 4 compares the injury rate for surgical set-
tings with the combined rate for all other hospital
settings; it shows that the surgical sharps injury
rate remained unchanged after passage of the
NSPA in 2000, and that the law almost exclusively
t
a
k
[
Figure 4 U.S. EPINet: comparison of surgical and non-s
injuries = 28,895 (excludes injuries occurring before use of detal injuries = 10,778 (excludes injuries occurring before
mpacted (and beneﬁted) non-surgical settings.
ack of adoption of safety-engineered devices,
uch as blunt suture needles and shielded scalpels,
argely accounts for this phenomenon.
It is important to underscore that global reduc-
ions in U.S. sharps injury rates were observed only
fter safety devices became the predominant tech-
ology; the low level of safety-device adoption
efore 2000 did not produce a large-scale reduc-
ion in rates. For device categories (suture needles
nd scalpels) in which adoption of safety alterna-
ives has remained low — blunt-tip suture needles
nd safety scalpels both have less than 5% mar-
et share — injury rates have not declined at all
43,44].
urgical injury rates, 1993—2003. 87 hospitals; total
vice).
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onclusions
.S. government regulations and legislation, ﬁrst
nitiated by OSHA in 1987, have been critical to
he successful implementation of prevention mea-
ures that protect U.S. HCWs from life-threatening
loodborne pathogens. The U.S. is unique in fos-
ering the development of a new generation of
afety-engineered sharp medical devices, and is the
rst country to nationally mandate their adoption.
he U.S. experience demonstrates the importance
nd effectiveness of safety-engineered needles and
harps in reducing sharps injuries and bloodborne
athogen exposures in healthcare settings.
The U.S. experience also showed that voluntary
doption of safety technology, without a legislative
andate, was ineffective in producing a large-scale
eduction in sharps injury rates. A signiﬁcant drop
n rates occurred only after an enforceable law was
nacted and safety-engineered devices became the
redominant technology.
U.S. legislation requiring safety-engineered
evices has notable strengths. First, it recognizes
hat safety devices are not available for every med-
cal application, and permits clinical judgment to
e used in such cases. Second, it requires the input
f HCWs in the process of evaluating and select-
ng safety devices, which is key to their acceptance
nd also results in valuable feedback for device
anufacturers. User input in each institution is
mportant because different devices may be appro-
riate for different healthcare facilities. Third, the
aw requires in-service training to ensure that new
evices are used consistently and correctly; the
mphasis on appropriate training has been criti-
al to implementing a new generation of devices.
ourth, the legislation does not favor any speciﬁc
ompany or device design, but instead provides a
erformance-based deﬁnition of safety-engineered
evices that allows for a variety of approaches. This
as been important in encouraging industry-wide
articipation, and has resulted in a range of prod-
ct designs and choices, which is necessary given
he diversity of medical procedures that are per-
ormed.
Although compliance with the requirement to
se safety devices, as reﬂected in market data,
as been high, there remain areas of weakness.
hile HCWs in non-hospital settings (clinics, private
octors’ and dentists’ ofﬁces, long-term care facil-
ties, free-standing laboratories, etc.) account for
pproximately 60% of the healthcare workforce in
he U.S. [45], adoption levels of safety-engineered
evices in these settings are generally about
5—35% below hospitals [40]. There is a lower
evel of enforcement in these independent facilities
t
c
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s well, and the consequences of not comply-
ng are perceived to be less. Within the hospital
nvironment, the surgical setting is least likely
o adopt safety-engineered devices, such as blunt
uture needles and shielded scalpel blades. Sur-
eons and anesthesiologists generally have been
esistant to new safety equipment. In 2007, how-
ver, the American College of Surgeons issued a
‘Statement on Sharps Safety’’ that recommended,
mong other practices, the use of blunt-tip suture
eedles and devices with engineered sharps injury-
revention features [46]. It remains to be seen
hether the ACS recommendation will have an
mpact.
The cost of safety technology is an issue in
very country, rich or poor. In the U.S., health-
are employers cannot use cost arguments to justify
ontinued use of conventional needles and sharp
evices. They may, however, use cost as one cri-
erion among others in choosing between different
afety-engineered alternatives.
The legislation passed in the U.S. created a
arge and permanent market for safety-engineered
evices. Major device manufacturers around the
orld are producing safety-engineered sharp
evices as a result of the demand created by the
.S. market. The initial costs for developing this
ew technology have been borne largely by the
.S. market. Manufacturing efﬁciencies have been
chieved and the cost of safety devices continues
o decline; new and more cost-effective products
re being designed as the market for safety devices
xpands globally. The greatest cost efﬁciencies
ill be achieved when safety-engineered devices
ecome the standard in every country. It is a goal
orth pursuing.
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